Harbor Capital Advisors Inc. Sells 871 Shares of Insulet Co. (NASDAQ:PODD)

Harbor Capital Advisors Inc. reduced its position in shares of Insulet Co. (NASDAQ:PODD) by 38.0% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 1,419 shares of the medical instruments supplier’s stock after selling 871 shares during the quarter. Harbor Capital Advisors Inc.’s holdings in Insulet were worth $370,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Integrated Wealth Concepts LLC lifted its position in Insulet by 1.7% during the third quarter. Integrated Wealth Concepts LLC now owns 2,561 shares of the medical instruments supplier’s stock valued at $596,000 after purchasing an additional 42 shares during the last quarter. Glenmede Trust Co. NA lifted its holdings in shares of Insulet by 2.3% in the 3rd quarter. Glenmede Trust Co. NA now owns 2,080 shares of the medical instruments supplier’s stock valued at $484,000 after acquiring an additional 47 shares during the last quarter. Wedmont Private Capital lifted its holdings in shares of Insulet by 3.5% in the 3rd quarter. Wedmont Private Capital now owns 1,433 shares of the medical instruments supplier’s stock valued at $326,000 after acquiring an additional 48 shares during the last quarter. OVERSEA CHINESE BANKING Corp Ltd grew its position in Insulet by 4.7% in the third quarter. OVERSEA CHINESE BANKING Corp Ltd now owns 1,076 shares of the medical instruments supplier’s stock worth $250,000 after acquiring an additional 48 shares in the last quarter. Finally, TD Private Client Wealth LLC increased its stake in Insulet by 32.6% during the third quarter. TD Private Client Wealth LLC now owns 228 shares of the medical instruments supplier’s stock worth $53,000 after acquiring an additional 56 shares during the last quarter.

Wall Street Analysts Forecast Growth

PODD has been the subject of a number of recent research reports. Raymond James lifted their target price on Insulet from $213.00 to $260.00 and gave the stock an “outperform” rating in a report on Monday, October 14th. Wells Fargo & Company boosted their price objective on shares of Insulet from $290.00 to $305.00 and gave the company an “overweight” rating in a research report on Wednesday, December 11th. Sanford C. Bernstein initiated coverage on shares of Insulet in a report on Wednesday, November 6th. They issued an “outperform” rating and a $300.00 target price for the company. Citigroup upped their price target on shares of Insulet from $283.00 to $310.00 and gave the company a “buy” rating in a report on Wednesday, December 11th. Finally, Morgan Stanley raised their price objective on shares of Insulet from $234.00 to $317.00 and gave the stock an “overweight” rating in a research note on Monday, November 11th. Three analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $272.81.

Insulet Stock Down 0.4 %

Shares of NASDAQ PODD opened at $267.04 on Wednesday. The stock has a market capitalization of $18.73 billion, a PE ratio of 45.73, a price-to-earnings-growth ratio of 4.12 and a beta of 1.22. The company has a current ratio of 3.68, a quick ratio of 2.80 and a debt-to-equity ratio of 1.21. Insulet Co. has a 12-month low of $160.19 and a 12-month high of $279.77. The stock’s fifty day simple moving average is $264.57 and its two-hundred day simple moving average is $230.93.

Insider Activity at Insulet

In other news, CAO Lauren Budden sold 915 shares of the firm’s stock in a transaction on Tuesday, December 10th. The stock was sold at an average price of $275.62, for a total value of $252,192.30. Following the completion of the sale, the chief accounting officer now owns 5,733 shares of the company’s stock, valued at $1,580,129.46. This trade represents a 13.76 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 0.47% of the stock is owned by corporate insiders.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.